INSIGHTS AT POLARIS: Expert advice, news, and what's new at Polaris.
AMERICAS TRANSPARENCY Significant Payments of Other Sorts ("SPOOS”) are a part of the FDA’s financial disclosure regulations, not CMS’s open payments requirements. “SPOOS” include payments made by a sponsor of a clinical study to an investigator/institution to support activities of theLearn More
Investment in long-term compliance solutions is on the rise. Three factors are driving that increased spending. The life sciences industry has faced many challenges in 2016 as global regulations andRead more
The final deadline for publication and submission of reports of transparency disclosures required by the European Federation of Pharmaceutical Industry Associations (EFPIA) arrived on June 30, 2016. Companies have nowRead more
Récemment dans le rapport de la Cour des Comptes, il est paru que les exigences de la loi Betrand présentent de nombreux défis pour les entreprises pharmaceutiques, notamment dans laRead more